Dupilumab was effective in improving disease severity and decreasing severity-associated serum biomarkers in pediatric atopic dermatitis (AD) patients after 28 weeks of treatment, according to real-world evidence from clinical practice.
New study reviews worldwide prevalence of mental health comorbidities in psoriasis patients
A new study has evaluated the worldwide prevalence of mental disorders such as depression, anxiety, and suicide in patients with psoriasis.
Acne incidence in preadolescents may be linked to age and BMI
According to a recent study, acne incidence in preadolescents is associated with increased age and higher body mass index (BMI).
Researchers develop new non-invasive burn assessment method
Researchers have developed a handheld imaging device using a neural network model that can non-invasively assess burns.
Upadacitinib effective for treating hand eczema in AD patients
Upadacitinib was found to be an effective treatment for hand eczema in patients with atopic dermatitis (AD) in a 16 week study.
Patients with comorbid PsA show decreased response to biologics for PsO
According to a recent study, patients with comorbid psoriatic arthritis (PsA) have a slightly decreased treatment response to biologics for psoriasis (PsO) than those without PsA.
Most psoriasis patients viewed comorbid obesity as unrelated
According to a recent study, most psoriasis patients view their comorbid obesity as unrelated to their skin condition.
Study shows smoking and obesity increase psoriasis risk
According to a new study, smoking and obesity-related factors such as body mass index and waist and hip circumference, are linked to an increased risk of psoriasis.
Study shows AD severity linked to societal economic burden in Sweden
Atopic dermatitis (AD) severity is associated with incremental societal costs in Sweden. Both direct and indirect costs are higher in patients with mild-to-moderate and severe AD than those without AD.
Topical calcineurin inhibitor use for AD shows no cancer risk, according to study
According to a new study, topical calcineurin inhibitors such as pimecrolimus and tacrolimus did not increase cancer risk in atopic dermatitis (AD) patients.
